NCT03749018 - Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaDiffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedIndolent Non-Hodgkin LymphomaMediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaTransformed Non-Hodgkin Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Give IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus